The novel immunotherapy naptumomab estafenatox, an anti-5T4 antibody fused with a staphyloccocal superantigen is under investigation as a treatment for a variety of different tumour types. However, the final analyses of a phase II/III clinical trial comparing the efficacy of naptumomab estafenatox administered with interferon (IFN)-α versus IFN-α monotherapy reveal no significant diiference in overall survival between patients who received naptumomab estafenatox plus IFN-α versus those who received IFN-α alone. Despite the failure to achieve any differences in overall survival, this approach might be effective in certain biomarker-defined patient subgroups.
References
Hawkins, R. E. et al. A randomized phase 2/3 study of naptumomab estafenatox + IFN-α vs IFN-α in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis. Clin. Cancer Res, http://dx.doi.org/10.1158/1078-0432.CCR-15-0580 (2016)
Rights and permissions
About this article
Cite this article
Sidaway, P. Naptumomab estafenatox ineffective in RCC. Nat Rev Urol 13, 182 (2016). https://doi.org/10.1038/nrurol.2016.41
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.41